Registry-based study on the effect and safety of Cre8™, Cre8 Evo ™, Amphilimus -eluting stent for coronary atherosclerotic lesions

Harmonizing Optimal Strategy for Treatment of coronary atherosclerotic lesions – Registry-based study on the effect and safety of Cre8™, Cre8 Evo ™, Amphilimus - eluting stent for coronary atherosclerotic lesions

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

CRIS

Registry ID

KCT0008521

Enrollment

2000

Registered

2023-06-13

Start date

2022-09-29

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Seoul National University Hospital

Lead Sponsor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Over 19 years of age who has been treated with a Cre8™ and Cre8 Evo ™ , stent for coronary artery disease who has agreed in writing to participate in this registry study

Exclusion criteria

Exclusion criteria: Pregnant women, lactating women, or women of childbearing age who are planning to conceive are excluded.

Design outcomes

Primary

Measure	Time frame
combined clinical events of Death, Myocardial infarction and Target Vessel Revascularization(TVR)	—

Secondary

Measure	Time frame
cardiogenic death;myocardial infarction;stent thrombosis;bleeding events	—

Countries

Korea, Republic of

Contacts

Public ContactPark sungjoon

Seoul National University Hospital

sungjoon111@daum.net+82-2-2072-3757

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026